Currently, Pliant Therapeutics Inc [PLRX] is trading at $1.41, up 0.71%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The PLRX shares have gain 11.90% over the last week, with a monthly amount drifted -8.44%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Needham downgraded its rating to Hold on March 04, 2025. On March 03, 2025, downgrade downgraded it’s rating to Hold. Leerink Partners downgraded its rating to a Market Perform. Wells Fargo downgraded its rating to a Equal Weight and reduced its price target to $4 on February 10, 2025. RBC Capital Mkts downgraded its rating to Sector Perform for this stock on February 10, 2025, and downed its price target to $4. In a note dated February 10, 2025, Oppenheimer downgraded an Perform rating on this stock.
This stock has fluctuated between a low of $1.10 and a high of $16.10 over the last 52 weeks. Currently, Wall Street analysts expect the stock to reach $2.5 within the next 12 months. Pliant Therapeutics Inc [NASDAQ: PLRX] shares were valued at $1.41 at the most recent close of the market. An investor can expect a potential return of 77.3% based on the average PLRX price forecast.
Analyzing the PLRX fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.64, Equity is -0.68 and Total Capital is -0.74. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.23.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.3650 points at the first support level, and at 1.3200 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.4400, and for the 2nd resistance point, it is at 1.4700.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Pliant Therapeutics Inc [NASDAQ:PLRX] is 11.03. As well, the Quick Ratio is 11.03, while the Cash Ratio is 3.26.
Transactions by insiders
Recent insider trading involved Coulie Bernard, President and CEO, that happened on Jan 17 ’25 when 52419.0 shares were sold. Chief Financial Officer, Cummings Keith Lamont completed a deal on Jan 17 ’25 to sell 20148.0 shares. Meanwhile, Chief Business Officer Hull Hans sold 15936.0 shares on Jan 17 ’25.
